Transcript
Comprehensive biomarker testing is the first step in precision medicine.
Knowing a patient's biomarker status may guide personalized treatment plans.
Clinical guidelines recommend comprehensive biomarker testing at diagnosis for all appropriate patients with advanced non small cell lung cancer or NSCLC, regardless of patient characteristics such as smoking history or race.
However, biomarker testing data for patients with advanced NSCLC suggests testing rates can be improved, especially in minorities.
Consider ordering comprehensive biomarker testing... that includes KRAS alongside other actionable molecular biomarkers for your eligible non small cell lung cancer patients.
Consider also making a plan to keep track of biomarker test results for future reference in the event of disease recurrence or progression.
Multidisciplinary tumor boards can also assist in interpreting biomarker results.
